ClinicalTrials.gg
CompletedNCT03530514Updated Mar 9, 2020

A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy Volunteers

A Phase 1 interventional study of REGN4461 and Placebo in Healthy Volunteers, sponsored by Regeneron Pharmaceuticals. Completed at 1 site in Belgium. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-09.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The primary objective of the study is to evaluate the safety and tolerability of REGN4461 in healthy participants. The secondary objectives of the study are to:

  • Characterize the Pharmacokinetic (PK) profile of single and repeated doses of REGN4461 and evaluate the effects of baseline covariates on PK profile
  • Estimate the effects of repeated doses of REGN4461 on body weight over 12 weeks in overweight and obese participants
  • Assess the effects of repeated doses of REGN4461 on ad lib energy intake in overweight and obese participants
  • Evaluate the effects of single and repeated doses of REGN4461 on soluble forms of lipid-regulating proteins levels over time
  • Assess the immunogenicity of single and repeated doses of REGN4461
Read the detailed description

This is a 2-part study of the safety, tolerability, PK and pharmacodynamic (PD) of single and repeated doses of REGN4461 in healthy participants. In Part A, healthy lean or overweight participants will be enrolled to evaluate the safety, tolerability, PK, and PD of single ascending intravenous (IV) and subcutaneous (SC) doses. Interim PK and safety information from Part A will be used to select the dose level, frequency, and mode of administration (IV or SC) for repeat dosing in Part B. In Part B, overweight/obese participants with body mass index (BMI) 25-40 kg/m2 will be enrolled to evaluate the safety, tolerability, PK, and PD of repeated doses of REGN4461 in 4 distinct cohorts defined by baseline leptin levels.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria

Part A:

  • Males and females 18 to 50 years of age, inclusive
  • (BMI) from 18.5 to \<30.0 kg/m\^2
  • Participant is judged by the investigator to be in good health and free from major comorbidities based on medical history, physical examination, laboratory safety tests performed at screening and/or prior to administration of initial dose of study drug

Part B:

  • Males and females 18 to 65 years of age, inclusive
  • Have a body mass index (BMI) from 25.0 to 40.0 kg/m\^2
  • Participant is judged by the investigator to be free from major comorbidities based upon medical history, physical examination, laboratory safety tests performed at screening and/or prior to administration of initial dose of study drug. Participants can have a history of mild hyperlipidemia and/or mild hypertension but should be on stable doses of lipid lowering or blood pressure lowering medicines for at least 2 months prior to screening

Key Exclusion Criteria

Part A:

  • History of type 1 or 2 diabetes or prediabetes or with fasting blood glucose (FBG) at screening ≥ 100mg/dL or with at screening of ≥ 5.7%.
  • Fasting LDL-C ≥ 130mg/dL, TG ≥ 250 mg/dL

Part B:

  • History of type 1 or 2 diabetes or with FBG at screening ≥ 126 mg/dL or with HbA1c at screening of ≥ 6.5%. A diagnosis of "pre-diabetes" is allowed.
  • Fasting LDL-C ≥ 160 or TG ≥ 500 mg/dL

Key Exclusion Criteria (Parts A and B):

  • Hospitalization (ie, >24 hours) for any reason within 60 days of the screening visit
  • History of hypothalamic amenorrhea or lipodystrophy.
  • Change in body weight of more than 5% over the past 3 months prior to screening.
  • Previous history of bariatric procedures for obesity (eg, sleeve gastrectomy, gastric bypass, banding, etc).
  • Procedures for weight reduction (eg, liposuction) or body contouring in the past 6 months.
  • Treatment with medications for (over-the-counter [OTC] or prescribed) weight loss (eg, lorcaserin, phentermine/topiramate, naltrexone HCl/bupropion HCl, liraglutide) in the past 3 months.
  • History of major psychiatric disorders, eating disorders (eg, bulimia, anorexia).
  • Current cigarette smoker or former smoker (cigarettes or e-cigarettes) who stopped smoking within 3 months prior to screening.
  • History of recreational drug (including marijuana) or alcohol abuse (>2 drinks per day) within a year prior to the screening visit.
  • History of infection or a positive hepatitis B surface antigen (HbsAg+) at screening
  • History of infection or HIV seropositive at the screening visit.
  • History of infection or positive hepatitis C antibody test result at screening.
  • Pregnant or breastfeeding women.

Note: Other inclusion/ exclusion criteria apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    Part A: Single dose cohort 1

    Cohort 1 will receive a single IV dose of REGN4461 or matching placebo

    Drug: REGN4461 · Drug: Placebo

  • Experimental
    Part A: Single dose cohort 2

    Cohort 2 will receive a sequential ascending single IV dose of REGN4461 or matching placebo

    Drug: REGN4461 · Drug: Placebo

  • Experimental
    Part A: Single dose cohort 3

    Cohort 3 will receive a sequential ascending single IV dose of REGN4461 or matching placebo

    Drug: REGN4461 · Drug: Placebo

  • Experimental
    Part A: Single dose cohort 4

    Cohort 4 will receive a sequential ascending single SC dose of REGN4461 or matching placebo

    Drug: REGN4461 · Drug: Placebo

  • Experimental
    Part A: Single dose cohort 5

    Cohort 5 will receive a sequential ascending single IV dose of REGN4461 or matching placebo

    Drug: REGN4461 · Drug: Placebo

  • Experimental
    Part A: Single dose cohort 6

    Cohort 6 will receive a sequential ascending single SC dose of REGN4461 or matching placebo

    Drug: REGN4461 · Drug: Placebo

  • Experimental
    Part A: Single dose cohort 7

    Cohort 7 will receive a sequential ascending single IV dose of REGN4461 or matching placebo

    Drug: REGN4461 · Drug: Placebo

  • Experimental
    Part A: Single dose cohort 8

    Cohort 8 will receive a single IV dose of REGN4461 or matching placebo

    Drug: REGN4461 · Drug: Placebo

  • Experimental
    Part A: Single dose cohort 9

    Cohort 9 will receive a single IV dose of REGN4461 or matching placebo

    Drug: REGN4461 · Drug: Placebo

  • Experimental
    Part B: Repeated dose cohort 10

    Cohort 10 will receive repeated IV or SC doses of REGN4461 or matching placebo

    Drug: REGN4461 · Drug: Placebo

Interventions

  • REGN4461

  • DrugPlacebo

    Placebo-matching REGN4461

06

What researchers measure

Primary outcomes

  1. Number of treatment-emergent adverse events (TEAEs)

    Time frame: Up to week 27

Secondary outcomes

  1. Concentrations of REGN4461 in serum over time

    Time frame: Up to week 27

  2. Percent change from baseline to week 12 in body weight in overweight or obese participants

    Time frame: Baseline to week 12

  3. Absolute change from baseline to week 12 in body weight in overweight or obese participants

    Time frame: Baseline to week 12

  4. Change from baseline in caloric intake in response to standardized meals in overweight or obese participants

    Time frame: Baseline to week 12

  5. Change in lipid-regulating protein levels over time after single doses of REGN4461

    Time frame: Up to week 16

  6. Change in lipid-regulating protein levels over time after repeated doses of REGN4461

    Time frame: Up to week 27

  7. Incidence of anti-drug antibodies to REGN4461 over time after single doses of REGN4461

    Time frame: Up to week 16

  8. Incidence of anti-drug antibodies to REGN4461 over time after repeated doses of REGN4461

    Time frame: Up to week 27

  9. Pharmacokinetic (PK) parameter: Area under curve (AUC) computed from time zero to the time of the last positive concentration (AUClast)

    Time frame: Up to week 27

  10. PK parameter: AUC computed across a dosing interval with length τ (AUCo-τ)

    Time frame: Upt to week 27

  11. PK parameter: peak concentration (Cmax)

    Time frame: Up to week 27

  12. PK parameter: time to Cmax (tmax)

    Time frame: Up to week 27

  13. PK parameter: clearance (CL)

    Time frame: Up to week 27

  14. PK parameter: trough concentration (Ctrough)

    Time frame: Up to week 27

07

Study locations

1 site
  • Regeneron Investigational Site
    Antwerp, Belgium
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Jan 2020, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2018
First posted
May 21, 2018
StartActual
Apr 24, 2018
Primary completionActual
Jan 27, 2020
CompletionActual
Jan 27, 2020
Last update
Mar 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03530514
Responsible party
Sponsor
First posted
May 21, 2018
Start date
Apr 24, 2018
Primary completion
Jan 27, 2020
Completion
Jan 27, 2020
Last update
Mar 9, 2020

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mibavademab

Start the discussion